The Relation of Serum Calcium and FBS with Vitamin D Deficiency among Type 2 Diabetic Patients

Background: Diabetes mellitus, especially Type 2, is a primary endocrine disorder that has become highly prevalent because of unhealthy food habits and sedentary lifestyle-related factors, and nowadays people of all ages all over Bangladesh report suffering from vitamin D deficiency despite having adequate sunshine at this latitude.Worldwide, the number of people who have diabetes is expected to more than double, from 171 million to 366 million people, by 2030, among them 90% with T2DM.Objective: To determine the relationship between Serum Calcium and Fasting Blood Sugar in Deficient Type 2 Diabetic patients.Material and Methods: A randomized, placebo-controlled interventional study was conducted with 44 diagnosed Diabetic patients (22 in the treatment group and 22 in the placebo group) who were on oral hypoglycemic agents, aged 30 to 70 years, enrolled between 1st October 2022 and 1st March 2023.Data collection has been done from Zainul Haque Sikder Women's College & Hospital.The study population was selected into treatment and placebo groups through a proper randomization procedure(SRS).The treatment group received 20,000 IU cholecalciferol weekly, and the placebo group received a placebo (Microcrystalline Cellulose BP), which was supplemented simultaneously with the treatment group for 3 months.Biochemical parameters (vitamin D, calcium, and FBS) were measured at baseline and after intervention.The Ethical Committee of the Faculty of Biological Science, University of Dhaka, has approved the research protocol.Results: The study found significant improvement in vitamin D levels among the treatment group(p=0.000)but no statistically significant difference in FBS or calcium levels between treatment and placebo groups after supplementation(p>0.05).Baseline comparability between groups was reasonable (no significant differences in socio-demographics).Conclusion: A favorable effect was observed between Vitamin D-deficient Type 2 diabetic patients and glycemic control (in terms of reduction in fasting blood glucose) over a 3-month treatment period.However, these effects were not significantly different.